Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 1, 2017

View Archived Issues

CinRx closes Series B financing

Carrick initiates phase I program with CDK7 inhibitor CT-7001

Patient recruitment ongoing in phase I/II trial of PCM-075 in patients with AML

First-in-human phase I trial of AMG-701 enrolling patients with multiple myeloma

NIH and partners launch Imbokodo HIV vaccine trial

Orpheris announces the results of meeting with the FDA regarding regulatory path for OP-101

Cardiac Hsl gene knockdown provides model of hypoxia tolerance

MicroRNA-4639 a potential plasma biomarker of early Parkinson's disease

Phase I study of PGDM-1400 and PGT-121 mAbs in HIV-infected and HIV-uninfected adults

EMA validates application for Opdivo plus Yervoy in advanced renal cell carcinoma

Serum CETP may identify mortality risk in hemodialysis patients

Solid Biosciences initiates IGNITE DMD phase I/II study of SGT-001

Zhejiang Hisun Pharmaceutical presents new epothilone derivatives

Luoda Biosciences and Nanjing Shiqi Pharmaceutical describe novel anticancer compounds

FDA approves FoundationOne CDx diagnostic test

Novel AMP-activated protein kinase activators generated at Shionogi

Enanta patents novel farnesoid X receptor agonists

Mavupharma Series A financing to fund STING Modulators

FDA approves once-monthly Sublocade to treat opioid use disorder

FDA grants fast track to Armagen's AGT-181 for the treatment of patients with Hurler syndrome

Astellas Pharma exercises option to acquire Mitobridge

U.K.'s MHRA reclassifies Viagra for sale as non-prescription, pharmacy medicine

Astellas files for Japanese approval of Gonax 12-week formulation for prostate cancer

Afstyla launched in Japan for the treatment of hemophilia A

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...